Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.

Cohen EE, Karrison TG, Kocherginsky M, Mueller J, Egan R, Huang CH, Brockstein BE, Agulnik MB, Mittal BB, Yunus F, Samant S, Raez LE, Mehra R, Kumar P, Ondrey F, Marchand P, Braegas B, Seiwert TY, Villaflor VM, Haraf DJ, Vokes EE.

J Clin Oncol. 2014 Sep 1;32(25):2735-43. doi: 10.1200/JCO.2013.54.6309. Epub 2014 Jul 21.

2.

Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial.

Martins RG, Parvathaneni U, Bauman JE, Sharma AK, Raez LE, Papagikos MA, Yunus F, Kurland BF, Eaton KD, Liao JJ, Mendez E, Futran N, Wang DX, Chai X, Wallace SG, Austin M, Schmidt R, Hayes DN.

J Clin Oncol. 2013 Apr 10;31(11):1415-21. doi: 10.1200/JCO.2012.46.3299. Epub 2013 Mar 4.

PMID:
23460709
3.

Multiple myeloma, version 1.2013.

Anderson KC, Alsina M, Bensinger W, Biermann JS, Cohen AD, Devine S, Djulbegovic B, Faber EA Jr, Gasparetto C, Hernandez-Illizaliturri F, Huff CA, Kassim A, Krishnan AY, Liedtke M, Meredith R, Raje N, Schriber J, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Weber D, Yahalom J, Yunus F, Shead DA, Kumar R.

J Natl Compr Canc Netw. 2013 Jan 1;11(1):11-7.

PMID:
23307977
4.

A randomized phase II study of cetuximab every 2 weeks at either 500 or 750 mg/m2 for patients with recurrent or metastatic head and neck squamous cell cancer.

Fury MG, Sherman E, Lisa D, Agarwal N, Algazy K, Brockstein B, Langer C, Lim D, Mehra R, Rajan SK, Korte S, Lipson B, Yunus F, Tanvetyanon T, Smith-Marrone S, Ng K, Xiao H, Haque S, Pfister DG.

J Natl Compr Canc Netw. 2012 Nov 1;10(11):1391-8.

5.

Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013.

Anderson KC, Alsina M, Bensinger W, Biermann JS, Cohen AD, Devine S, Djulbegovic B, Faber EA Jr, Gasparetto C, Hernandez-Ilizaliturri F, Huff CA, Kassim A, Krishnan AY, Medeiros BC, Meredith R, Raje N, Schriber J, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Tricot G, Weber DM, Yahalom J, Yunus F, Kumar R, Shead DA; NCCN (National Comprehensive Cancer Network).

J Natl Compr Canc Netw. 2012 Oct 1;10(10):1211-9.

PMID:
23054875
6.

Chronic myelogenous leukemia.

O'Brien S, Abboud CN, Akhtari M, Altman J, Berman E, DeAngelo DJ, Devine S, Fathi AT, Gotlib J, Jagasia M, Moore JO, Pinilla-Ibarz J, Radich JP, Reddy VV, Shah NP, Shami PJ, Smith BD, Snyder DS, Wetzler M, Yunus F; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2012 Jan;10(1):64-110. No abstract available.

PMID:
22223870
7.

Multiple myeloma.

Anderson KC, Alsina M, Bensinger W, Biermann JS, Chanan-Khan A, Cohen AD, Devine S, Djulbegovic B, Faber EA Jr, Gasparetto C, Huff CA, Kassim A, Medeiros BC, Meredith R, Raje N, Schriber J, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Tricot G, Weber DM, Yahalom J, Yunus F; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2011 Oct;9(10):1146-83. No abstract available. Erratum in: J Natl Compr Canc Netw. 2011 Dec 1;9(12):xxv.

PMID:
21975914
8.

Feasibility and efficacy of neoadjuvant sunitinib before nephron-sparing surgery.

Silberstein JL, Millard F, Mehrazin R, Kopp R, Bazzi W, DiBlasio CJ, Patterson AL, Downs TM, Yunus F, Kane CJ, Derweesh IH.

BJU Int. 2010 Nov;106(9):1270-6. doi: 10.1111/j.1464-410X.2010.09357.x.

9.

NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas.

Zelenetz AD, Abramson JS, Advani RH, Andreadis CB, Byrd JC, Czuczman MS, Fayad L, Forero A, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kaminski MS, Kim YH, Lacasce AS, Mughal TI, Nademanee A, Porcu P, Press O, Prosnitz L, Reddy N, Smith MR, Sokol L, Swinnen L, Vose JM, Wierda WG, Yahalom J, Yunus F.

J Natl Compr Canc Netw. 2010 Mar;8(3):288-334. No abstract available.

PMID:
20202462
10.

NCCN clinical practice guidelines in oncology: multiple myeloma.

Anderson KC, Alsina M, Bensinger W, Biermann JS, Chanan-Khan A, Cohen AD, Devine S, Djulbegovic B, Gasparetto C, Huff CA, Jagasia M, Medeiros BC, Meredith R, Raje N, Schriber J, Singhal S, Somlo G, Stockerl-Goldstein K, Tricot G, Vose JM, Weber D, Yahalom J, Yunus F; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2009 Oct;7(9):908-42. No abstract available.

PMID:
19878637
11.

Incidence and risk factors of bisphosphonate-associated osteonecrosis of the jaws.

Stumpe MR, Chandra RK, Yunus F, Samant S.

Head Neck. 2009 Feb;31(2):202-6. doi: 10.1002/hed.20941.

PMID:
18853454
12.

Non-Hodgkin's lymphomas.

Zelenetz AD, Advani RH, Byrd JC, Czuczman MS, Damon LE, Duvic M, Fayad L, Forero A, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kaminski MS, Kim YH, Lacasce AS, Nademanee A, Olsen EA, Porcu P, Press O, Prosnitz L, Smith MR, Sotomayor EM, Vose JM, Yahalom J, Yunus F; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2008 Apr;6(4):356-421. No abstract available.

PMID:
18433606
13.

Multiple myeloma. Clinical practice guidelines in oncology.

Anderson KC, Alsina M, Bensinger W, Biermann JS, Chanan-Khan A, Comenzo RL, De Castro CM, Djulbegovic B, Farag S, Huff CA, Meredith R, Schriber J, Shrieve D, Singhal S, Smith MR, Stockerl-Goldstein K, Vose JM, Weber D, Yahalom J, Yunus F; National Comprehensive Cancer Network (NCCN).

J Natl Compr Canc Netw. 2007 Feb;5(2):118-47. No abstract available.

PMID:
17335683
14.

Phase II trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with HER2(+) metastatic breast cancer.

Jahanzeb M, Mortimer JE, Yunus F, Irwin DH, Speyer J, Koletsky AJ, Klein P, Sabir T, Kronish L.

Oncologist. 2002;7(5):410-7.

15.

Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer.

Rocha Lima CM, Savarese D, Bruckner H, Dudek A, Eckardt J, Hainsworth J, Yunus F, Lester E, Miller W, Saville W, Elfring GL, Locker PK, Compton LD, Miller LL, Green MR.

J Clin Oncol. 2002 Mar 1;20(5):1182-91.

PMID:
11870159

Supplemental Content

Loading ...
Support Center